The regulatory landscape for red yeast rice (RYR) is undergoing significant change. With growing concerns about monacolin K, the European Food Safety Authority (EFSA) NDA Panel has raised serious safety alerts—even at very low intake levels. As stricter regulations are anticipated, it is imperative for the nutraceutical industry to proactively transition toward safer, regulation-friendly alternatives.
At SunWay Biotech, we are leading the way forward.
Introducing Ankascin® 568
Our patented, clinically proven, monacolin-free fermented red yeast rice ingredient offers a next-generation solution for cardiovascular and metabolic health—delivering broad-spectrum benefits without the regulatory risks associated with traditional red yeast rice.
✔ The Ankascin® 568 Advantage:
-
Regulatory-compliant: Safe for long-term use under current and future guidelines
-
Comprehensive health benefits: Supports cholesterol balance, blood sugar control, cardiovascular health, blood pressure regulation, and cognitive function
-
Science-backed efficacy: Validated by 5 proprietary clinical studies and over 130 scientific publications
-
Superior safety profile: No drug interactions and no severe adverse effects
As the regulatory environment tightens, the path to success lies in adopting innovative, clinically supported, and compliant ingredients. Ankascin® 568 empowers you to create products that are not only effective but sustainable for the future.
👉 Visit our website to learn more: Scientific Evidence – How Does it work?
📩 Let’s connect! Reach out today to explore how Ankascin® 568 can strengthen your next formulation.
